The 13th world congress on gastrointestinal cancer: new progress of bevacizumab in treating colorectal carcinoma
10.3760/cma.j.issn.1006-9801.2012.01.001
- VernacularTitle:第十三届世界胃肠道肿瘤大会:贝伐单抗治疗结直肠癌新进展
- Author:
Desen WAN
;
Hui LIU
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Bevacizumab;
Therapy
- From:
Cancer Research and Clinic
2012;24(1):1-3,7
- CountryChina
- Language:Chinese
-
Abstract:
To summarize the latest study results about anti-angiogenic therapy for colorectal cancer (CRC) reported in the 13th world congress on gastrointestinal cancer, and review the latest progress of bevacizumab in treating colorectal carcinoma combined with related literatures.From the internal medicine point of view, bevacizumab is emphasized that to be applied earlier would gain benefit as soon as possible,and to be applied continuously would gain more benefit.The curative effect of second-line therapy has been confirmed renewedly.In the surgery point, bevacizumab neoadjuvant treating liver metastases in metastatic colorectal carcinoma (mCRC) can improve the disease-free rate and the operable rate significantly, and has favorable tolerance.In addition,bevacizumab can decrease the hepatic injury induced by chemotherapy safely and effectively.
